Michael Klein - Icad Ex Director

ICAD Stock  USD 1.56  0.04  2.63%   

Director

Mr. Michael S. Klein serves as Executive Chairman of the Board, Chief Executive Officer of iCAD Inc. Mr. Michael Klein has served as the Chief Executive Officer at Inflection Point Consulting, an executive coaching and consulting firm with a focus on medical technology, biopharma and healthcare services, since December 2014. Prior to that, he was the Chief Executive Officer at US HIFU, LLC, a global leader in minimally invasive high intensity focused ultrasound technologies, from December 2011 to November 2014. From April 2011 to December 2011, Mr. Klein was the President of the Civco Radiation Oncology Division within Roper Industries, a diversified industrial company that produces engineered products for global niche markets. He was President and Chief Executive Officer of Xoft, Inc., a medical device company, a position he held from December 2004 until the sale of Xoft to the Company in December 2010. Prior to joining Xoft, from 2000 to 2004, Mr. Klein served as Chairman, President and Chief Executive Officer of R2 Technology, Inc., a breast and lung cancer computer aided detection company. Mr. Klein received a Bachelor of Arts degree from the University at Albany, SUNY since 2018.
Age 70
Tenure 6 years
Professional MarksMBA
Address 98 Spit Brook Road, Nashua, NH, United States, 03062
Phone603 882 5200
Webhttps://www.icadmed.com
Klein also received his M.B.A. from the New York Institute of Technology and completed his postgraduate Executive Education Studies at Harvard University and Babson College. We believe Mr. Kleins qualifications to serve on our Board of Directors include his significant experience as an executive in the healthcare industry, his understanding of our products and markets and his previous tenure on our board.

Icad Management Efficiency

The company has return on total asset (ROA) of (0.1032) % which means that it has lost $0.1032 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2052) %, meaning that it created substantial loss on money invested by shareholders. Icad's management efficiency ratios could be used to measure how well Icad manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -0.24. In addition to that, Return On Capital Employed is expected to decline to -0.23. At present, Icad's Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 11.18, whereas Other Current Assets are forecasted to decline to about 681 K.
The company currently holds 461 K in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. icad inc has a current ratio of 3.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Icad until it has trouble settling it off, either with new capital or with free cash flow. So, Icad's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like icad inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Icad to invest in growth at high rates of return. When we think about Icad's use of debt, we should always consider it together with cash and equity.
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire. Icad operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 136 people. icad inc (ICAD) is traded on NASDAQ Exchange in USA. It is located in 98 Spit Brook Road, Nashua, NH, United States, 03062 and employs 67 people. Icad is listed under Health Care Technology category by Fama And French industry classification.

Management Performance

icad inc Leadership Team

Elected by the shareholders, the Icad's board of directors comprises two types of representatives: Icad inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Icad. The board's role is to monitor Icad's management team and ensure that shareholders' interests are well served. Icad's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Icad's outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew Sassine, Director
Stephen Sarno, Interim Officer
Michelle Strong, Chief Officer
Jonathan Go, Sr. VP of RandD
Zack Kubow, IR Contact Officer
Scott Areglado, Vice President Controller
Brian Testa, Chief Officer
Susan Wood, Director
Richard Christopher, CFO, Executive Vice President
Vasu Avadhanula, Chief Officer
Lawrence Howard, Chairman of the Board
Anthony Takazawa, Director Relations
Robert Goodman, Director
Elliot Sussman, Independent Director
Dana Brown, CEO President
Kevin Burns, President, CFO, COO, Treasurer and Secretary
Somu Subramaniam, Independent Director
Rakesh Patel, Director
Eric Lonnqvist, Chief Officer
Steven Rappaport, Independent Director
Annette Heroux, Vice Administration
Michael Klein, Ex Director
Stacey Stevens, Sr. VP of Marketing and Strategy
Anthony Ecock, Independent Director
Rachel Brem, Independent Director
Jeffrey Sirek, Chief Officer
Kenneth Ferry, CEO and Director
Bill Keyes, Senior Operations
Peter Graham, Senior Sales

Icad Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Icad a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Icad in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Icad's short interest history, or implied volatility extrapolated from Icad options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether icad inc is a strong investment it is important to analyze Icad's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Icad's future performance. For an informed investment choice regarding Icad Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in icad inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the icad inc information on this page should be used as a complementary analysis to other Icad's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Icad Stock analysis

When running Icad's price analysis, check to measure Icad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Icad is operating at the current time. Most of Icad's value examination focuses on studying past and present price action to predict the probability of Icad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Icad's price. Additionally, you may evaluate how the addition of Icad to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Bonds Directory
Find actively traded corporate debentures issued by US companies
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Money Managers
Screen money managers from public funds and ETFs managed around the world
Is Icad's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Icad. If investors know Icad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Icad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.27)
Revenue Per Share
0.676
Quarterly Revenue Growth
0.023
Return On Assets
(0.10)
Return On Equity
(0.21)
The market value of icad inc is measured differently than its book value, which is the value of Icad that is recorded on the company's balance sheet. Investors also form their own opinion of Icad's value that differs from its market value or its book value, called intrinsic value, which is Icad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Icad's market value can be influenced by many factors that don't directly affect Icad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Icad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Icad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Icad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.